San Francisco, CA, USA and Milano, Italy, March 22, 2018 – Trianni, Inc. (“TRIANNI”) and Enthera, S.r.l. (“ENTHERA”) jointly announced today that ENTHERA has entered into a license agreement for The Trianni Mouse™, a best-in-class monoclonal antibody discovery platform.
“TRIANNI is pleased to add ENTHERA as an important new licensee,” stated Dr. David Meininger, TRIANNI’s Chief Business Officer. “TRIANNI continues to innovate to the benefit of our growing list of partners. We’re excited to enable ENTHERA’s antibody discovery efforts through this agreement.”
“We are confident that the access to TRIANNI’s technology will dramatically improve our discovery efforts. It is a real pleasure entering into this collaboration” declared Prof. Paolo Fiorina, Chief Scientific Officer at Enthera.
No financial details were disclosed.
About Trianni, Inc.
Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. TRIANNI’s lead technology, The Trianni Mouse™, is a powerful, next-generation platform enabling efficient generation of fully-human monoclonal antibodies. TRIANNI’s transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology making it a best-in-class therapeutic antibody discovery platform. The company is headquartered in San Francisco, CA. Additional information about TRIANNI is available through its corporate website, www.trianni.com.
About Enthera, S.r.l.
Enthera S.r.l. is a new Italian biotech start-up which mission is to find new therapeutic approaches to treat diabetes and related gastrointestinal complication (enteropathy), as well as other intestinal disorders sharing the same biological pathway. Its name comes from the crasis of the terms entero (referring to the intestine) and therapy.
Enthera was founded by BiovelocITA in October 2016 in collaboration with the scientists: Prof. Paolo Fiorina and Dr. Francesca D’Addio.